EUS-Guided Biliary Drainage in Patients With Inoperable Malignant Distal Biliary Obstruction and Failed ERCP: a Prospective Feasibility Multicenter Trial

Johns Hopkins University96 enrolled

Overview

This research is being done to study the safety and feasibility of recruiting patients eligible for EUS-guided biliary drainage (EGBD). Our goal is to prospectively study safety and effectiveness of this procedure.

Our central hypothesis is that EGBD is equally effective and safe to percutaneous transhepatic biliary drainage (PTBD) but is associated with better quality of life than PTBD in patients with inoperable malignant distal biliary obstruction who have failed prior ERCP. Furthermore, EGBD may be associated with decreased procedure-related costs. Patients who undergo PTBD usually require multiple procedures for stent exchange/upsize. Our initial study will be a prospective multicenter feasibility study that will include patients with inoperable distal biliary obstruction who have failed ERCP. If feasibility is demonstrated, our goal will be to compare EGBD and PTBD in a randomized multicenter international trial with a crossover design.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Malignant Distal Biliary Obstruction

Interventions

EUS-guided biliary drainageOTHER

Based on the patient's condition, the will receive: * Rendezvous technique * Direct transluminal access transesophageal technique * Direct transluminal access transduodenal technique * or direct transluminal access using transgastric approach

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Consecutive adult patients (18-80 years of age) with jaundice due to inoperable (by EUS and/or CT criteria or due to health status) malignant distal (more than 2cm distal to hilum) biliary obstruction and who have failed prior ERCP attempt. Failure is considered to be 2 unsuccessful attempts, according to each institution's definition of "failed" procedure (patients may be consented for EGBD prior to repeat ERCP due to higher likelihood of failure). One failure at outside institution and one failure at your institution can be considered as total of two failures. * Ability to give informed consent Exclusion Criteria: * Unable to give informed consent * Life expectancy \< 1month * Pregnant or breastfeeding women * Acute gastrointestinal bleeding * Coagulopathy defined by prothrombin time \< 50% of control; PTT \> 50 sec, or INR \> 1.5), or on chronic anticoagulation * Inability to tolerate sedated upper endoscopy due to cardio-pulmonary instability or other contraindication to endoscopy. * Prior total gastrectomy, Roux-en-Y gastric bypass, esophagectomy and sleeve gastrectomy * ESLD with portal hypertension, varices, and/or ascites * Liver metastases burden \> 30%

Locations (13)

University of Colorado

Aurora, Colorado, United States

University of Florida

Gainesville, Florida, United States

Florida Hospital

Orlando, Florida, United States

Outcomes

Primary Outcomes

Effectiveness (Clinical success is defined as drop in bilirubin by 50%)

Clinical success is defined as drop in bilirubin by 50% at 2 weeks and to below 3 (level

Time frame: From date of intervention up to 4 weeks

Secondary Outcomes

Quality of life (QOL)

Determine improvement in QOL of patients after PTBD. QOL will be assessed using the EORTC-QLQ-30 instrument (at baseline, 1 week, 4 weeks and 12 weeks after the procedure).

Time frame: From date of intervention up to 12 weeks

Procedure-related costs

Cost will be determined according to Medicare reimbursement of billed CPT codes. The cost of all related follow-up procedures will be included (e.g. cost of PTBD in case of failed EGBD, cost of managing complications, cost of reintervention in case of stent occlusion, etc)

Time frame: Lifetime (These patients have a life expectancy of less than 2 years)

Number of required procedures

Time frame: From date of intervention up to death (These patients have a life expectancy of less than 2 years)

Technical success

This is defined as success of stent placement in the desired location as determined endoscopically and radiographically. In addition, success of each step during EUS will be tracked and recorded (e.g. needle puncture, cholangiography, tract dilation, etc

Time frame: Intra- and post intervention (These patients have a life expectancy of less than 2 years)

Stent patency

Determine stent patency which is defined as time period between stent placement and need for reintervention for signs and symptoms of recurrent biliary obstruction

Time frame: Lifetime (These patients have a life expectancy of less than 2 years)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.